

# VBC Release Highlights

July 15, 2022

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

## MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard has been updated to reflect 2022 specification changes for:

Measure	Update	Practice Impact
MIPS 450: HER2 Targeted Therapies for Breast Cancer	<ul style="list-style-type: none"> <li>The checked Adjuvant box in the Line of Therapy category has been removed from the Numerator.</li> <li>Numerator credit will now be met by a patient receiving chemotherapy within 6 months of diagnosis.</li> <li>Telehealth visits have been removed from the Denominator qualifier.</li> </ul>	Practices will notice a significant increase in denominator and numerator due to the removal of the adjuvant chemotherapy requirement.
MIPS 128: Body Mass Index Screening and Follow-Up Plan	Technical refinements were made to better capture palliative care denominator exclusions through CPT codes and the iKnowMed Generation 2 Palliative Care Chart Alert.	Practices may notice a decrease in denominator and numerator.

## Advance Care Planning Performance and Activity Dashboards

Q3 2022 data will be available Monday, July 18, 2022, from the time period drop-down.

### Status of Dashboard Updates for 2022

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed and Practice Insights is currently working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.

Measure	Description
<b>MIPS Quality Measures Dashboard</b>	
#047	Advance Care Plan
#104	Combination Androgen Deprivation Therapy for Prostate
#110	Preventive Care and Screening: Influenza Immunization
#128	Body Mass Index (BMI) Screening and Follow-Up Plan
#130	Current Medications Documentation
#134	Depression Screening
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
#374	Closing the Referral Loop
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#453	Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Metastatic Cancer
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal

Measure	Description
	Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#12	COVID-19 Vaccinations
<b>OCM Performance Measures Dashboard 1H 2022</b>	
OCM 4A	Pain Intensity Quantified
OCM 4B	Plan of Care for Pain
OCM5	Depression Screening